The lack of thorough and reliable clinical data on the way medicines affect children requires strengthened safety monitoring and vigilance of medicinal products. This is the fundamental message of Promoting safety of medicines for children, released today by the World Health Organization (WHO).
Pharmaceutical company GenVec’s malaria vaccine candidate is well-tolerated and induces an immune response, according to results from a Phase I/II clinical trial presented by the company at the Malaria Vaccines for the World Conference at the Royal Society of Medicine in London.
New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS (pioglitazone HCI) and its benefits regarding improved blood glucose and blood lipid levels for patients with type 2 diabetes.
Biopharmaceutical researchers have found a protein in blood they say is linked to all stages of lung cancer but which rarely shows up in the blood of people without the disease. Testing for this protein might help physicians decide whether smokers or others at high risk for lung cancer should be referred for lung imaging, say investigators, who presented their findings today in Atlanta, Georgia at the American Association for Cancer Research’s second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Attorney General Andrew M. Cuomo and New York City Mayor Michael Bloomberg filed a joint lawsuit against the maker of Vioxx for misrepresenting the dangers the drug posed to its users.
GlaxoSmithKline (GSK) and Sepracor Inc. (Nasdaq: SEPR) announced an agreement for the commercialisation of Sepracor’s eszopiclone product for all markets worldwide (excluding the U.S., Canada, Mexico and Japan).
Thanks to a $1.6 million grant from the Welch Foundation, a coalition of six Gulf Coast institutions is launching a new initiative to develop innovative computational and chemical techniques intended to speed the development of new drugs and molecular tools for biomedical science.
A sweeping review of research studies of aspartame says there is no evidence that the non-nutritive sweetener causes cancer, neurological damage or other health problems in humans.
Patients are being put at risk because some hospital doctors are not always following warning procedures over known drug allergies, new research launched at the British Pharmaceutical Conference (BPC) in Manchester shows.
By guiding an enzyme down a new evolutionary pathway, a team of University of Wisconsin-Madison researchers has created a new form of an enzyme capable of producing a range of potential new therapeutic agents with anti-cancer and antibiotic properties.